Your search found 5 Results
Journal of the Association of Nurses in AIDS Care. 1999; 10(1):17-20.There is a need for increasing international collaboration in the search for a safe and effective HIV vaccine. In addition to the ethical issues that must be considered in conducting any clinical research, unique issues arise in vaccine research and in international research. Careful deliberation and guideline development regarding the ethics of international vaccine research was the focus of a series of recent consultations sponsored by Joint United Nations Programme on HIV/AIDS (UNAIDS) around the world. (author's)
Consultative meeting on: "Accelerating an HIV / AIDS vaccine for developing countries: How can international development agencies help? South Africa, Tuesday, July 27, 1999.
[Unpublished] 1999. 11 p.On July 27, 1999, the South African Medical Research Council hosted a consultative meeting on ways in which international agencies could accelerate development of an AIDS vaccine that is effective and affordable for developing countries. 37 senior policy-makers from South Africa and the region, South African researchers, and other stakeholders participated in the meeting. The issues paper, "Accelerating an AIDS vaccine for developing countries: Issues and Options for the World Bank," and the report of the European Union (EU) Brussels Vaccine Consultation served as background for the meeting. Issues regarding the global status and prospects of HIV/AIDS vaccine development, the South Africa AIDS Vaccine Initiative, the analysis of the business costs and response of a major South African employer, the results of the industry study and issues in estimating potential demand, and the options the World Bank and EU are considering were emphasized in the meeting.
Consultative meeting on accelerating the development of an HIV / AIDS vaccine for developing countries: issues and options for the World Bank, World Bank New Delhi office, New Delhi, India, Wednesday 18 August 1999.
[Unpublished] 1999. 11 p.Because of the profound economic impact of AIDS, the World Bank considers AIDS as a core economic development issue and has made a major commitment to continue and expand lending for AIDS prevention and care. In addition, an internal Task Force is exploring innovative ways that the Bank can stimulate rapid development of an AIDS vaccine that will be effective and affordable in low-income countries. Representatives of the Bank's AIDS Vaccine Task Force and the New Delhi Office met with Indian policy-makers on August 18 to share the findings of the Task Force and to solicit the policy-makers' views on how the Bank can accelerate AIDS vaccine development in India and globally. The participants felt that a strategic plan for development of an AIDS vaccine in India should be part of the overall national AIDS control strategy. The World Bank can assist in this program through future lending for vaccine research and development; International Finance Corporation financing of improvements and expansion of vaccine production; and technical assistance in the design of studies of Indian industry's perspectives on AIDS vaccines and of the potential public and private demand. (author's)
[Unpublished] .  p.This paper presents the findings and recommendations of the World Bank AIDS Vaccine Task Force, formed in April 1998 to identify how institutions can accelerate the development of an AIDS vaccine for developing countries, as part of its broader program to combat AIDS, and in collaboration with its international and development partners. The World Bank has already taken important steps to reduce the impact of the AIDS epidemic through lending for AIDS prevention and care, analytic publications, participation in international partnerships, and launching of an anti-AIDS initiative in Africa. Nevertheless, progress on potentially one of the most important interventions--a preventive AIDS vaccine--is slow. This is caused by several barriers, such as the cost of the technology for an HIV vaccine, lack of financial investments from international agencies, and policy constraints. Based on existing studies of the economics of AIDS vaccine development and demand, review of a broad range of existing and potential mechanisms to promote an AIDS vaccine, and consultations with industry, international donors, and developing countries, the recommendations of the AIDS Vaccine Task Force for the promotion of international efforts in HIV vaccine development are highlighted.
Issues related to scientific, technical, population, and behavioral preparation in WHO-selected sites.
In: International Symposium on Biomedical Research Issues of HIV Infection in Thailand. Bangkok, Thailand, January 31 - February 2, 1994. Sponsors: Thailand Health Research Institute, Harvard AIDS Institute, Ministry of Public Health of Thailand, Center for Vaccine Development, Mahidol University. Cambridge, Massachusetts, Harvard AIDS Institute, 1994. 23-4.For the past three years, the World Health Organization (WHO) has been working with national authorities and scientists from the four countries which have been identified as appropriate for the establishment of WHO-sponsored sites for HIV vaccine evaluation: Brazil, Rwanda, Thailand, and Uganda. National plans for HIV vaccine development and evaluation have been prepared by the countries and endorsed by the WHO. The plans detail the national policy and nationally acceptable guidelines for the approval and initiation of HIV vaccine-related activities. They provide specific recommendations for the selection of participating institutions, for interactions with other national and international AIDS research programs, for infrastructure strengthening, and for training and specific research activities. In preparation for phase III vaccine efficacy trials, the following priority research areas have been identified: virologic, clinical, epidemiologic, and sociobehavioral research. Research in these areas is discussed. It is also important to develop a comprehensive public information strategy to help maintain community support and political commitment. Finally, trials must be conducted with only the highest ethical standards.